Annual Report 2022 5 two drug development programs, namely the ChromaTM and SofraTM technology platforms. Focusing on cancer and inflammation respectively, these two platforms represent our ambition to advance the most promising life-saving therapies through the discovery, preclinical and clinical phases, building the value of our new assets and exploring outlicensing opportunities at critical steps along the way. These two new programs deepen and broaden the company’s operations as Veyonda® trials continue. Enrolments and patient treatments are progressing, and new hospitals such as the prestigious Mayo Clinic have been added to those participating in the trials, reflecting our strategy of working with world-class partners wherever we can. We will keep shareholders updated on key clinical trial milestones as and when they occur, and the team remains focused on exploring commercial opportunities for Veyonda® in a global market with a significant need for new cancer treatments. In regard to financials, we have a stable cash position, with the management team keeping a close eye on costs and directing resources where they will produce the greatest effect to meet our strategic goals. Overall, we are well-positioned to take the company forward, having strengthened our pipeline and progressed our trials over the previous 12 months. On behalf of the Board, I would like to thank our shareholders for their ongoing support as we work hard to deliver value across the entirety of our operations, and build a company that will deliver sustainable success both now and well into the future. Yours Sincerly, Fred Bart Chairman
RkJQdWJsaXNoZXIy MjE2NDg3